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Abstract
Background—Randomized clinical trials in pediatric aplastic anemia (AA) are rare and data to 
guide standards of care are scarce.
Procedure—Eighteen pediatric institutions formed the North American Pediatric Aplastic 
Anemia Consortium to foster collaborative studies in AA. The initial goal of NAPAAC was to 
survey the diagnostic studies and therapies utilized in AA.
Results—Our survey indicates considerable variability among institutions in the diagnosis and 
treatment of AA. There were areas of general consensus, including the need for a bone marrow 
evaluation, cytogenetic and specific fluorescent in-situ hybridization assays to establish diagnosis 
and exclude genetic etiologies with many institutions requiring results prior to initiation of 
immunosuppressive therapy (IST); uniform referral for hematopoietic stem cell transplantation as 
first line therapy if an HLA-identical sibling is identified; the use of first-line IST containing horse 
anti-thymocyte globulin and cyclosporine A (CSA) if an HLA-identical sibling donor is not 
identified; supportive care measures; and slow taper of CSA after response. Areas of controversy 
included the need for telomere length results prior to IST, the time after IST initiation defining a 
treatment failure; use of hematopoietic growth factors; the preferred rescue therapy after failure of 
IST; the use of specific hemoglobin and platelet levels as triggers for transfusion support; the use 
of prophylactic antibiotics; and follow-up monitoring after completion of treatment.
Conclusions—These initial survey results reflect heterogeneity in diagnosis and care amongst 
pediatric centers and emphasize the need to develop evidence-based diagnosis and treatment 
approaches in this rare disease.
Keywords
Acquired aplastic anemia; NAPAAC; diagnosis; treatment
Introduction
Aplastic anemia is a rare disorder most with a bi-modal age presentation, arising both early 
and late in life (1). Although aplastic anemia is relatively rare in childhood, its medical 
impact remains high with life-threatening consequences entailing complex medical therapies 
and potential long-term complications. Published evidence to guide clinical management of 
aplastic anemia in children remains scarce. The rapidly growing armamentarium of tests for 
genetic factors contributing to aplastic anemia raises new questions with regard to diagnostic 
workup and treatment decisions.
Methods
Because of the paucity of data to guide medical management of aplastic anemia in children, 
eighteen pediatric hematology centers with an interest in aplastic anemia have initiated the 
North American Pediatric Aplastic Anemia Consortium (NAPAAC). The NAPAAC 
collaborative working group conducted a survey of its members to determine current 
practices for the diagnostic workup, treatment, and medical management of pediatric 
aplastic anemia in North America.
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Results
Diagnosis definition, severity classification and initial diagnostic evaluations
We surveyed 18 children’s hospitals in the United States and Canada regarding laboratory-
based diagnostic and treatment practices for pediatric aplastic anemia. All institutions 
completed the survey in its entirety. Sixty percent of the respondents used criteria for severe 
aplastic anemia (SAA) modified after those described by Camitta and colleagues (2) with an 
absolute neutrophil count (ANC) <500/μL, platelets < 20,000/μL and absolute reticulocytes 
<20,000/μL and bone marrow (BM) cellularity <25% for age. Forty percent of respondents 
noted that two out of three blood count criteria along with marrow hypocellularity were 
sufficient. The absolute reticulocyte count (ARC) required for diagnosis varied among some 
institutions between <40,000 to <60,000/μL. An ANC <200/μL uniformly defined very 
severe aplastic anemia (vSAA) from SAA. Three respondents used the ARC to distinguish 
SAA (ARC <60,000/μL) from vSAA (ARC <40,000/μL). Taken together, these institutions 
see approximately 75–80 new patients ages 1–18/year with acquired aplastic anemia.
Moderate AA (mAA) was defined in 60% of the centers as Hb <10 g/dL, ANC <1,500/μL, 
platelets <50,000/μL, ARC <40,000/μL, and BM cellularity 25–50%. Some institutions used 
a platelet count <60,000/μL and/or BM cellularity <50% for the diagnosis of mAA. Several 
institutions utilized broader criteria comprising any abnormal decreased blood count with a 
hypocellular BM and not fulfilling the criteria for SAA or vSAA.
All 18 centers uniformly included BM cytogenetics in the diagnostic work-up at 
presentation (Table I). Sixty percent of institutions included fluorescent in situ hybridization 
(FISH) studies for monosomy 7, 5q-, and 8 chromosome gain, while 22% included 
chromosomes 22q-, 20, and 9 FISH probes. Over 90% of those who do cytogenetics or FISH 
would await these results prior to IST or hematopoietic stem cell transplantation (HSCT). 
Two-thirds of respondents analyzed BM for T, B, and CD34+ cells by flow cytometry. 
Eighty-nine percent evaluated paroxysmal nocturnal hemoglobinuria (PNH) by flow 
cytometry. Almost all (94%) respondents performed HLA typing of patient and siblings, 
while 78% of institutions routinely included parental typing at the time of diagnosis.
Diagnostic tests to exclude viral causes of AA included EBV, CMV, and hepatitis A, B and 
C in 80% of centers. The status of HIV, HSV, VZV, or HHV6 was also evaluated in 33–
44% of centers, while parvovirus B19 was assayed in <17% of institutions. Eleven percent 
of respondents did not do viral testing at initial evaluation. Of the centers that do viral 
testing, up to 70% would await results prior to therapy. Approximately half of respondents 
measured vitamin B12 and folate levels, while a similar proportion (44%) assessed immune 
function by measuring lymphocyte numbers, T and B cell subsets and immunoglobulin 
levels.
Evaluations for constitutional etiologies—Most respondents excluded inherited bone 
marrow failure syndromes which would lead to alternative therapies (Table I). Eighty-nine 
percent of institutions performed testing for Fanconi anemia (FA). Fifty-eight percent of 
those institutions which perform these tests delay IST or HSCT until results are available. 
Sixty-seven percent performed telomere length analysis for dyskeratosis congenita (DC). If 
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telomere length testing was suspicious for DC, follow-up genetic testing was typically sent. 
Additionally, a diagnosis or suspicion of DC or FA led to testing of family members. Some 
centers utilized DC testing upon re-evaluation of patients whose disease is refractory to IST 
and for research purposes (see below). As an initial molecular diagnostic workup, 71% 
ordered sequencing of the Shwachman-Bodian-Diamond syndrome gene (SBDS), while 40% 
of respondents evaluated genes causing DC (DKC1, TERT, TERC, TINF2, NOP10/NHP2) 
and the and amegakaryocytic thrombocytopenia-associated gene (c- MPL, the 
thrombopoietin receptor). Biochemical, radiographic, and ultrasound investigations for 
internal physical anomalies for SBDS, FA and Diamond-Blackfan Anemia (DBA), were 
infrequently (0–22%) performed as a routine diagnostic workup for aplastic anemia.
Initial Treatment of SAA
There was consensus to proceed with a matched sibling donor (MSD) HSCT if a donor was 
identified at the time of initial diagnosis of SAA or vSAA. Thirty eight percent of 
respondents, however, would consider IST as primary treatment despite the availability of a 
MSD under certain circumstances. These circumstances include family concerns regarding 
fertility (39%), family preference for IST (28%), an anticipated delay of greater than 6–8 
weeks until HSCT (33%), and significant psycho-social barriers to BMT (28%). If the blood 
counts dropped during CSA tapering, 78% would repeat bone marrow testing, and 39% 
would perform additional work-up including evaluation for inherited marrow failure (e.g. 
telomere length and SBDS testing, if not previously performed) and flow cytometry for 
PNH. In this situation, 83% would increase the CSA dose in an effort to re-induce 
remission. Seventy-five percent of respondents did not feel comfortable using autologous 
cord blood as a source for HSCT.
Immunosuppression Therapy—All but one of the institutions used an IST regimen 
consisting of anti-thymocyte globulin (ATG) and cyclosporine A (CSA). The remaining 
institution utilized high-dose cyclophosphamide alone for immunosuppression. The majority 
of institutions (67%) consider initiating IST within 21 days of diagnosis to be very important 
for successful outcome. All institutions would utilize horse ATG rather than rabbit ATG for 
initial IST. Most commonly the patients receive a test dose of ATG followed by 40 mg/kg/
dose daily for 4 days, but 25% of institutions treat patients for 5 days. The ATG is given 
over 4–10 hours with most centers using an 6–8 hour infusion duration. Half of the centers 
escalate the dose of ATG slowly on the first day of treatment. Premedication with 
diphenhydramine and acetaminophen is common. Methylprednisolone is added by the 
majority of centers to minimize the risk for serum sickness as well as to reduce infusion 
reactions. Most protocols include intravenous methylprednisolone 2 mg/kg/day with ATG, 
given every 6 or 12 hours, which is changed to oral prednisone to complete a 4–14 day 
course followed by a tapering schedule. The institutions vary with respect to the location 
where IST is carried out, utilizing either positive pressure single occupancy rooms (50%), 
standard single occupancy rooms (44%), an open general hematology ward with two or 
more patients (28%), or a bone marrow transplant ward (17%).
ATG is uniformly given with CSA. Most commonly used CSA formulations were Neoral® 
or Gengraf®, both of which are modified formulations. The starting dose of CSA ranged 
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from 2.5–7.5 mg/kg/dose given every 12 hours to maintain CSA trough levels of 150–250 
μg/L, measured by monoclonal antibody (33%) assay or HPLC (28%) in local laboratories. 
Some institutions utilized a range of 100–200 μg/L while others utilized 200–400 μg/L.
Supportive Care
Practices for blood product support are summarized in Table I. Leukoreduced/”CMV-safe 
products” were universally utilized while 59% of institutions specifically requested CMV-
negative donors if the patient’s initial CMV serology is negative. Irradiated blood products 
are specifically requested by 80% of those surveyed (44% of institutions irradiate all blood 
products).
There is also variability in packed red blood cell transfusion practices as outlined in Table II. 
Based on concerns with alloimmunization and iron overload, there was a uniform approach 
to utilize as few transfusions as possible to keep the patient relatively asymptomatic. Nearly 
all institutions (87%), however, agree that there is a lower limit of acceptable hemoglobin 
for which most patients should be transfused regardless of symptoms, although this level 
varied significantly from 5.0–8.0 G/dL. Some programs utilize patient-specific parameters 
including clinical symptoms, degree of reticulocytopenia, proximity of a weekend, distance 
from the hospital, expected follow up and planned activities to develop a tailored approach 
to transfusion therapy.
A significant number (71%) of institutions prophylactically maintain platelet counts at least 
above 10,000/μl throughout treatment and the majority of these (92%) attempt to maintain 
the platelet count at least above 20,000 /μl during administration of ATG (Table II). 
Granulocyte transfusions are used very rarely in the treatment of pediatric patients with 
aplastic anemia. In these instances they are employed only in the setting of refractory or life-
threatening infection in patients with severe neutropenia and no anticipated immediate 
neutrophil recovery.
Thirty-seven percent of responding institutions report using granulocyte colony stimulating 
factor (G-CSF) in patients from the beginning of therapy (Table III). Sixty-nine percent of 
respondents said they would use G-CSF in the setting of an active infection and no ANC 
recovery. GM-CSF is occasionally used in combination with G-CSF if there is an active 
infection and the patient’s ANC has not responded to G-CSF.
Prophylactic antimicrobial practices are summarized in Table IV. Most institutions provide 
Pneumocystis jiroveci prophylaxis throughout the treatment course. Seventy-two percent of 
institutions use antifungal medications. However, 22% of the institutions surveyed do not 
use any prophylactic antibacterial or antifungal agents regardless of blood counts. Those 
institutions that provide antibiotic prophylaxis generally discontinue the medications once 
the ANC has met a specific threshold, ranging from 500–1000/μl. The most commonly used 
broad-spectrum antibiotics reported are ciprofloxacin and levofloxacin; the most commonly 
reported anti-fungal agents are fluconazole and voriconazole. Acyclovir prophylaxis is used 
by some institutions.
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Participants were asked to comment on neutropenic precautions and vaccination policy. Free 
text comments ranged from not providing any specific precautions, using “common sense” 
regarding people who are obviously ill, avoiding construction and demolition sites, to 
specific instructions regarding cooking foods, hand washing, bathing daily, wearing of 
masks and other instructions. Patients are uniformly instructed to seek medical attention for 
any temperature elevation. Instructions regarding returning to school were also quite varied 
from “any time they are not in the hospital” to more detailed recommendations. Similarly, 
recommendations regarding immunizations were varied from “no set policy and no 
restrictions”, no live virus vaccines, to administration after specific time periods and/or 
keyed to the absolute lymphocyte count.
Follow-Up and Evaluation of Treatment Responses
The majority of survey respondents used a variety of measures as treatment response 
markers justifying a continuation of IST. A complete response (CR) to IST was defined as 
return to normal blood counts. A partial response (PR) was present when the patient was 
transfusion independent in the setting of continued abnormal counts. These definitions were 
consistent across all institutions. Only 22% of respondents felt that positive changes in more 
than one cell line were required to indicate a treatment response. However, less than half of 
institutions (44%) used a specific ANC and/or platelet threshold to define a minimal 
response. Moreover, the specific threshold value used in these institutions varied widely, for 
ANC from 200 to 1000/μL and for platelets from 20 to 100 × 103/ μL. All respondents 
considered failure to respond to IST by lack of attainment of transfusion independence and 
ANC <500/μL in 6 months post treatment initiation as treatment failure although some 
institutions considered 3 months post-treatment initiation as an early indication of IST 
failure.
Upon achievement of a complete response, there was considerable variation in evaluations 
performed prior to weaning CSA (Table V). Thirty-nine percent of surveyed institutions 
recommended a repeat BM aspirate and biopsy with cytogenetic evaluation while 28% 
specifically recommended no repeat testing. Seventeen percent of institutions performed 
PNH and CBC screening only. However, for patients who achieved only a stable partial 
response, a higher proportion of survey respondents (61%) would perform BM aspirate and 
biopsy prior to weaning therapy, whereas only 6% would do no further testing. One-third 
(33%) of respondents would continue CSA for a period ranging from 2–12 months beyond 
the time a stable partial response is achieved in order to determine whether further count 
improvement would occur before considering weaning therapy. There was consensus among 
all respondents that CSA should not be discontinued as soon as a complete response is 
established; however, there was considerable variability among respondents with regard to 
the duration of full dose CSA therapy from the time of therapy initiation (range 3 –15 
months), and specifically in the duration of consolidation treatment with full dose CSA after 
achieving complete remission (range 2–12 months).
Once treatment is discontinued, most respondents included routine clinic visits (61%) and 
blood counts (72%) as part of ongoing monitoring. However, the period of frequent 
monitoring after therapy discontinuation ranged from 3–12 months for patients with CR and 
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from 3–24 months for patients with stable PR, with blood counts every 0.5–2 months. 
Thirty-one percent of institutions would perform follow-up bone marrow exam once off 
therapy with CR or stable PR annually. Some institutions would perform at least one bone 
marrow exam with cytogenetics following therapy cessation, particularly for patients with 
stable PR.
With regard to long-term monitoring after recovery, about 80% of respondents reported a 
consistent approach at their institution, but the specifics of the monitoring protocols varied 
widely. The frequency of routine physical exams and blood counts during later follow-up 
varied from every 2 months to every 12 months. Sixty-six percent would consider 
discharging patients with CR from their hematology clinics at 5–10 years post-therapy 
cessation, whereas only 11% would discharge a patient with stable partial response. Notably, 
nearly 10% of respondents stated they would never discharge a patient with aplastic anemia 
from follow-up. All respondents agreed that a bone marrow aspirate with cytogenetics 
should be performed with a change in blood counts indicative of recurrence or worsening of 
marrow failure or of malignant transformation.
Treatment of Resistant and Relapsed Disease
Lack of response to initial IST—With regard to treatment options when there was no 
response to IST with the patient still meeting criteria for SAA, 72% of respondents would 
refer the patient for HSCT and/or start a search for a matched unrelated donor (MUD). If no 
acceptable MUD was available for a patient who failed IST, most centers would consider a 
second course of ATG/CSA. Alternative second line therapies, other than a second course of 
ATG/CSA, included eltrombopag (33%), cyclophosphamide (28%), and alemtuzumab 
(28%). Some centers would consider haploidentical HSCT in the absence of an acceptable 
MUD. For the second course of ATG, 13% of respondents would use horse ATG, 27% 
would use horse ATG unless there had been a severe reaction to the initial treatment, 20% 
would use rabbit ATG, and 40% would use the opposite form of ATG to the one given 
initially.
Relapse on treatment—For patients whose counts were declining after an initial 
response to IST while still on CSA, 78% of respondents would repeat the bone marrow 
aspirate, biopsy, and cytogenetics. Eighty-three percent would increase the dose of CSA to 
reach therapeutic levels if a taper had been started. Twenty-two percent would continue the 
current CSA dose (assuming that there were adequate blood levels of CSA) unless and until 
criteria for SAA developed again. No respondents indicated that they would immediately 
repeat treatment with ATG before criteria for SAA were reached. None of the surveyed 
institutions would utilize MUD HSCT for first line therapy.
Relapse off treatment—Fifty-six percent of respondents would re-start treatment as soon 
as there was a clear trend of recurrent marrow failure in patients off treatment. Seventeen 
percent would continue to observe until the patient met the criteria for SAA again. Sixty-one 
percent advocated “rescue” treatment for first relapse after IST with ATG/CSA. Among 
those who would treat with IST as first-line therapy for relapse, 73% would start searching 
for a donor at the same time as initiation of the second IST, but two respondents would start 
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a search for a donor only if there were no response to the second IST within 3 or 6 months. 
If no acceptable donor were found, for a second (or higher) relapse, 61% would consider 
repeating IST. A variety of other second-line therapies would be considered with similar 
frequency, including cyclophosphamide, eltrombopag and alemtuzumab. Less frequently 
used approaches in this setting included danazol and haploidentical HSCT.
Discussion
Severe aplastic anemia in children and adolescents is a rare disease with an estimated 
incidence of 1–3 cases per million (3, 4). The rarity of pediatric aplastic anemia poses 
difficulties for establishing guidelines for front-line treatment, salvage therapies, and 
supportive care. To address this challenge, a group of pediatric hematologists formed the 
North American Pediatric Aplastic Anemia Consortium. As a first step toward the 
development of diagnostic and therapeutic protocols, we surveyed 18 prominent pediatric 
hematology services. We found considerable variability in diagnostic work-up, supportive 
care, and the approach to patients with disease that is refractory to treatment or with relapsed 
disease.
Congruent with published algorithms for the initial treatment of acquired SAA in the 
pediatric age group (5–7), all surveyed institutions recommend HSCT if a MSD is identified. 
In light of improved outcomes of MUD for acquired SAA, some have proposed upfront 
therapy with a 10/10 HLA-A, -B, -C, -DRB1, -DQ high resolution MUD HSCT (8). 
However, the NAPAAC centers uniformly recommended IST, rather than MUD, if an HLA-
matched sibling donor was not identified due to the morbidity and mortality still associated 
with MUD in this setting.
All surveyed institutions preferentially use horse- rather than rabbit-derived ATG in their 
ATG-CSA regimens, a choice supported by results of a randomized trial demonstrating 
significantly lower response rates and survival with rabbit ATG (9). Although this trial did 
include children, it was not powered to evaluate pediatric patients as an independent 
variable. A retrospective study in children has recently been published (10). Therefore, 
whether horse ATG is superior to rabbit ATG in the pediatric population remains to be 
determined (11). The timing and duration of the CSA taper varied widely among 
respondents. Whether these differences translate into differences in relapse rates is 
unknown. Overall the majority of supportive care practices were consistent with published 
reviews (7, 12). However, some practice differences and deviations from published literature 
highlighted persistent, important management questions.
The use of upfront IST as first line therapy in the absence of MSD and transfusion practices 
were the areas of most consistency amongst surveyed institutions. More than a third of 
institutions surveyed reported using G-CSF from the onset of disease despite a multi-center, 
randomized study that demonstrated no difference in overall or event-free survival (13). 
Since this study did demonstrate reduced numbers of febrile events and in-patient hospital 
days, the variable practices may reflect differences in importance placed on costs versus 
risks of side effects of G-CSF. Antimicrobial prophylaxis was an interesting areas of 
divergence in practice. Twenty-two percent of the respondents use no prophylaxis. Three 
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fourths use prophylaxis against Pneumocystis jiroveci as recommended by a recent review 
(7) although the literature is not definitive on Pneumocystis sp. as a frequent complication in 
aplastic anemia outside the setting of HSCT (14). Similarly, use of antibacterial and 
antifungal agents was common in spite of their controversial efficacy in prolonged 
neutropenia (7, 15).
For patients with disease refractory to initial IST, only a minority recommended repeat IST 
treatment unless no MUD was available. If a patient initially responded but was becoming 
more cytopenic during CSA taper, the large majority of respondents return to full dose CSA 
treatment. For patients who “relapsed” off treatment, the majority of respondents would 
promptly initiate “rescue” treatment with ATG/CSA, but would simultaneously pursue the 
availability of a MUD transplant.
Summary
Acquired aplastic anemia is a rare disorder and randomized clinical trials in pediatric 
aplastic anemia are infrequent (16, 17, 18) although some adult trials include small numbers 
of children. While reported in Japanese, Korean and European populations (19–22), large, 
multi-institutional studies focused on North American patients have not been described. 
Standards of care in North America are currently institution-specific. While the results 
presented from this survey of multiple pediatric institutions demonstrate some areas of 
consensus in diagnostic work-up and treatment, a great deal of variability exists. These data 
suggest opportunities to standardize care and develop multi-institutional prospective trials to 
compare treatment approaches and outcomes of pediatric AA in North America with those 
of other regions and collaborative groups, with the goal of advancing the field with new 
therapeutic interventions.
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Table I
Diagnostic Workup
Test % Centers
Bone Marrow Asp/Bx 100%
Cytogenetics 100%
HLA typing of siblings 94%
Chromosome breakage analysis-MMC1/DEB2 89%
PNH3 Screen by Flow 89%
EBV4, CMV5 83%
Hepatitis screen 78%
SBDS6 gene sequencing 71%
Telomere length 67%
FISH (chr 5, 7, 8) 61%
BM Flow for T, B, CD34 67%
Immunological work-up 55%
Vit B12, Folate 50%
DC7 Genetic Testing 43%
HSV8, VSV9, HHV610 33%
Ferritin 28%
Pancreas U/S 22%
Kidney U/S 16%
Skeletal survey/Hand film 0%
1
MMC is defined as Mitomycin C.
2
DEB is defined as Diepoxybutane.
3
PNH is defined as Paroxysmal Nocturnal Hemoglobinuria.
4
EBV is defined as Epstein-Barr Virus.
5CMV is defined as Cytomegalovirus.
6SBDS is defined as Shwachman–Bodian–Diamond Syndrome.
7
DC is defined as Dyskeratosis Congenita.
8
HSV is defined as Herpes Simplex Virus.
9VSV is defined as Vesicular Stomatitis Virus.
10
HHV6 is defined as Human Herpesvirus 6.
Pediatr Blood Cancer. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Williams et al. Page 12
Table II
Blood product utilization
Blood product preparation
 Leukoreduced blood products 100%
 Routine extended cross matching 20%
 Radiated blood products specifically requested 81%
 All blood products radiated at institution 44%
 Use CMV negative product if initial serology is negative 59%
Red cell administration
 Maintain RBC above a certain level (6 – 8 g/dL) 50%
 Transfuse RBC only when patient is symptomatic 31%
 Use minimal transfusion to keep patients asymptomatic 88%
 Have lower acceptable hemoglobin level (5 – 8 g/dL) 88%
 Think that excessive transfusion delays recovery 20%
Platelet administration
 Maintain platelets above a certain level during ATG1 82%
  10,000/μl 8%
  20,000/μl 64%
  30,000/μl 14%
  50,000/μl 14%
 Prophylactically transfuse platelets in steady state 71%
  10,000/μl 91%
  15,000/μl 8%
Granulocyte Transfusions
 Utilization
  Sometimes 13%
  Rarely 63%
  Never 25%
1ATG is defined as Anti-Thymocyte Globulin.
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Table III
Myeloid growth factor usage
G-CSF1
 Routine use throughout treatment 37.5%
 Use for infection with neutropenia 68.8%
GM-CSF2
 Use for infection if no response to G-CSF 23%
 Use for duration of active infection 38%
1G-CSF is defined as Granulocyte Colony-Stimulating Factor.
2GM-CSF is defined as Granulocyte Macrophage Colony-Stimulating Factor.
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Table IV
Antimicrobial prophylaxis
Antimicrobial agent % Centers Throughout First month
No prophylactic antibiotics 22%
Bactrim 28% 100% 0%
Aerosol pentamidine 39% 86%
Fluconazole 33.3% 66.7% 33.3%
Voriconazole 39% 86%
Other 44%
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Table V
Lab tests prior to tapering cyclosporine
Complete response:
 Bone marrow aspirate/biopsy/cytogenetics 39%
 PNH1 17%
 No further testing 28%
 Other 16%
Partial response:
 Bone marrow aspirate/biopsy/cytogenetics 61%
 No further testing 6%
 Other 33%
1
PNH is defined as Paroxysmal Nocturnal Hemoglobinuria.
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